Mode
Text Size
Log in / Sign up
Phase 3 N=184 Randomized Quadruple-blind Treatment

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

Traumatic Brain Injury

Enrolled (actual)
184
Serious AEs
18.5%
Results posted
Sep 2012
Primary outcome: Primary: Disability Rating Scale: Functional Status — 17.3; 18.7; 17.1; 17.8 units on a scale — p=0.007

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Amantadine Hydrochloride (Drug); Placebo (Drug)
Age
Pediatric, Adult, Older Adult · 16+ yrs
Sex
All
Sponsor
JFK Medical Center
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Disability Rating Scale: Functional Status
17.3; 18.7; 17.1; 17.8 0.007 sig
SECONDARY
JFK Coma Recovery Scale-Revised: Neurobehavioral Status
15.8; 14.2; 15.7; 15.1 0.045 sig

Summary

This is a controlled trial of amantadine to improve level of function following severe traumatic brain injury. The purpose of this study is: 1. To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves functional recovery from the vegetative and minimally conscious states 2. To determine whether amantadine-related gains in function persist following drug discontinuation 3. To determine the safety profile of amantadine in patients with disorders of consciousness

Eligibility Criteria

Inclusion Criteria

  • Individuals between ages 16 and 65 with traumatic brain injury as defined by the TBI Model System syllabus (i.e., damage to brain tissue caused by an external mechanical force as evidenced by loss of consciousness or post-traumatic amnesia due to brain trauma, skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical or mental status examination).
  • Individuals are at least 4 weeks but less than 16 weeks post-injury and have a Disability Rating Scale (DRS) score at enrollment of 12 or greater, and no consistent command following or functional communication (as defined by the JFK.

Exclusion Criteria

  • Women who are pregnant,
  • Individuals with missile-type penetrating brain injury,
  • Premorbid major CNS/developmental abnormality (e.g., mental retardation, prior significant brain damage, etc.),
  • History of more than 1 seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) in the 4 weeks prior to enrollment (individuals with premorbid idiopathic epilepsy are eligible to enroll under two conditions: a) if their pre-injury seizure frequency was less than once/month and they have had no more than 1 seizure/month since injury and b) if a clear provocation was present that would otherwise disqualify a subject, the subject can be enrolled, since these events would not be considered idiopathic),
  • Prior exposure to AH post-TBI,
  • Unwillingness to discontinue or change confounding psychotropic drugs prior to enrollment, OR
  • Allergy or medical contraindication to AH and significant impairment of renal function (as evidenced by a calculated creatinine clearance of < 60 ml/min).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00970944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search